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ent of pretransplant disease status. The overali survival was better 
in CML patients transplanted in chronic phase (45-55%) or ALL 
patients transplanted in CR1 (33%7 whether from RD or URD (P 
< 0.057. There was no statistically significant difference in the 
relapse rate between RD & URD transplants for both ALL & 
CML patients with relapse mortality being 30% vs. 20% (p - 0.4) 
for ALL and 8% vs. 4% for CML (p=0.08). Acute GvHD of grade 
III or IV severity was observed in i5 % of the RD patients a  
compared to 27% of the URD patients. In conclusion, allogeneic 
transplantation from an URD at our institution appears to have 
equivalent outcome to transplant from RD for patients with CML 
or ALL. Transplantation f marrow from URD is reasonable and 
effective therapy for patients with CML or ALL who are candi- 
dates for allogeneic transplant, but has no RD. 
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EXTRACORPOREAL PHOTOPHORESIS AND PENTOSTATIN REDUCED 
INTENSITY PREPARATIVE REGIMEN: RESULTS IN PATIENTS WITH 
MYELODYSPLASTIC SYNDROME 
Chart, G.; Fos~, IV.; Klein, A.; SpJrlgzle, K.; 3/ii/ler, K. Tufts New Eng 
lm~d Medical Ce~teJ; Boston,, 3/IA. 
Substantial morbidity and mortality limits allogeneic stem cell 
transplantation for Myelodysplastie Syndrome (MDS) to 
younger patients with lower risk MDS. Sixteen patients (6M, 
10F), median age 53 years (range 32 to 70), with de novo (n=12) 
or therapy-related (n=4) NIDS underwent a reduced intensity 
preparative regimen of extracorporeal photophoresis for 2 days, 
pentostatin 8mg/m2 by continuous infusion over 48 hours, and 
600cGy TBI, followed by allogeneie bone marrow (n=15) or 
peripheral blood (n=l) stem cell infusion. GVHD prophylaxis 
consisted of cyelosporine A by continuous infusion and 
methotrexate. FAB subtypes included: RA (n=l), RARS (n=l), 
RAEB (n=10), RAEBT (n=3), and CMML (n=l). IPSS scores 
included: Low (n=l), Intermediate-1 (n=7), Intermediate-2 (n=5), 
and High (n=3). GVHD risk factors included: prior autoBMT 
(n=2), 5/6 HLA matched related donor (n=4), 6/6 matched unre- 
lated donor (n=4), age>50 years (n=10), and cytomegalovirus 
seropositivity (n=8). At a median follow-up of 10 months (range 
1-23), 14/16 patients developed full donor chimerism at engraft- 
ment with (n=l) or without (n=13) DLI. Nonrelapse mortality 
was 0% after 100 days and i9% after 1 year. Grade II and III-IV 
acute GVHD occurred in 7% and 14% of patients. Limited and 
extensive chronic GVHD developed in 25% and 42% of 
patients. One year relapsed free and overall survival was 60% 
and 63%. Patients died of disease progression failing engraft- 
ment (n-2), or acute (n=l) or chronic (n=3) GVHD. GVHD 
severity, nonrelapse mortality, relapse free and overall survival 
were similar among FAB or IPSS subtypes, but 6/6 matched 
related donors had less grade II-IV acute GVHD (p=0.0241) and 
better overall survival (p=0.0004). An extracorporeal pho- 
tophoresis and pentostatin reduced intensity preparative r gimen 
in high-risk MDS patients results in high rates of engraftment 
and survival with low rates of acute GVHD and disease relapse, 
but a high incidence of extensive chronic GVHD remains prob- 
lematic. 
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PERIPHERAL BLOOD STEM CELL VERSUS MARROW DONATION: 
EXPERIENCES OF 942 NMDP DONORS 
SzL, itze'r, G.EJ, Goycoolea, if.M J, Ha~7~aha, A.GJ; Dezz,, M J; Conifer, 
D.L.e; King, R.ff. 2 1. Medich~e, University of Pittsba~'gh 3/Iedical Cen- 
ter, Pittsbztrgh, PA; 2. National Mar'row Donor Program, MiTzneapo- 
lis, MN. 
The findings presented here represent the first comprehensive 
effort to examine psychosocial nd physical reactions to donation 
among Peripheral Blood Stem Cell (PBSC) versus marrow 
donors. Until recently, the PBSC donation procedure was used 
only infrequently among allogeneic donors, and then only in the 
context of second-time donation. In 1999, the NMDP imple- 
mented a PBSC donation protocol for first-time donors, and data 
collection for this project began. Longitudinal questionnaire data 
concerning donor demographic and psychosocial characteristics 
and donation-related decision processes and outcomes were gath- 
ered from 353 first-time PBSC donors (82% response) and a ran- 
domly selected comparison sample of 589 marrow donors (83% 
response) 2 weeks pre-donation, and 2 weeks post-donation. 
PBSC and marrow donors were virtually identical in terms of 
demographic characteristics and how quickly they made the dona- 
tion decision. Both groups felt equally prepared for donation, had 
low levels of ambivalence about donation, perceived the donation 
as moderately physically stressful, and felt good about having 
donated. However, PBSC donors were less likely than marrow 
donors to (a) have been encouraged (p<.001) or discouraged 
(p<.001) from donating by others, (b) report medical (p<.001) and 
family concerns (p<.01), (c) have donation related side effects and 
a longer post-donation recovery time (p<.001), and (d) perceive 
the donation as more painful than expected (p<.01). PBSC donors 
were more likely to have longer-term health concerns about dona- 
tion (p<.001). Conversely, although marrow donors had more 
physical difficulty with donation, they reported better mental 
health (p<.05), and higher self esteem (p<.01) post-donation. 
Overall, as compared to marrow donors, PBSC donors had less 
physical difficulty with donation, but more donation-related long- 
term health concerns and fewer psychosocial benefits. These find- 
ings provide strong evidence that PBSC is less physically demand- 
ing than marrow donation, and that the procedure is 
well-accepted by donors. 
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TEST DOSE PHARMACOKINETICS (PK) DIRECTED INTRAVENOUS 
BUSULFAN (IVBU) DOSING FOR HEMATOPOIETIC STEM CELL TRANS- 
PLANT (HSCT) PREPARATIVE REGIMENS 
Dickey, A.G.; Teresi, FV.M.; ~mghm~, I4~P.; Sal=man, D.E. UAB 
BMT Program, Bhwzing,~aJ:~, AL. 
Variation in the area under the concentration x time curve 
(AUC) for oral bu has been documented to result in a substantial 
risk of over or under treatment with excess risk of toxicity or 
relapse. The use of 1YBU reduces intra-patient variation in AUC 
by eliminating variation in absorption and clue to vomiting, 
although variation due to metabolism remains. In order to more 
accurately achieve a target AUC during the preparative r gimen, 
dose adjustment based on PK is necessary. This is typically done 
using PK determined on first dose administered resulting in 2 to 8 
doses of the typical 16 dose regimen being given before dose cor- 
rection. In this study patients were scheduled to receive 600mg of 
phenytoin the night before the test dose and then continued at 300 
mg twice daily until after the 16th dose. We performed PK studies 
following an IVBU test dose (15 mg/m2) to 8 adult patients at 
least 2 days prior to beginning a 16-dose IVBU containing BMT 
preparative regin, en. AUC was determined using an accurate 5- 
sample strategy analyzed using a single compartment, first order 
elimination model in the WinNonlin software as previously pub- 
lished by our group. We then chose the dose for administration as
first dose in the full 16-dose preparative regimen according to a 
linear assumption [First Dose = (Target AUC X Test Dose)/Test 
Dose AUC]. The Predicted Dose varied from the Target Dose as 
a result of rounding. Repeat PK was performed on the first dose to 
determine the utility of this approach (see table). In 5 patients the 
test dose PK predicted first dose AUC with less than 8% variation. 
The remaining 3underestimated first dose by an average of 18%. 
A phenytoin level obtained on one of those patients was 3.5 
whereas phenytoin levels on 3 of the 4 patients with low variation 
averaged >7%. These data suggest that better phenytoin loading 
or use of an alternate strategy for seizure prophylaxis will allow 
dosing precision with BU in HSCT preparative regimens. A great 
deal of research as been done defining maximum tolearted osing 
in preparative r gimens for allogeneic and autologous transplanta- 
tion; current research is heavily focused on defining minimum 
necessary dose for allogeneic transplantation. The dosing preci- 
sion permitted by PK directed therapy will permit research to 
define the optimum dose for each clinical setting. 
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STEM CELL TRANSPLANTATION (SCT) FOR PATIENTS WITH FAN- 
CONI'S ANEMIA (FA) WITH LOW DOSE CYCLOPHOSPHAMIDE (CY) 
AND ANTITHYMOCYTE GLOBULINS (ATG) WITHOUT THE USE OF 
RADIATION THERAPY, A PROSPECTIVE STUDY 
Ayas, M.F.; Al-J~fii, A.H.; ALMahr, M.; I~lrao~d, M.; Mltstafa, 
M.M.; Mol*,rsa, E.; Shalaby, L.; El-Solb, H. KiJ~g Faisal Specialist Hos- 
pital & Resea~vh Ce,lte'r. Depart77zeJ~t of Pediatric He~tzatology-O*~colo- 
gy, Riyadh, Smldi Arabia. 
Background: Radiation therapy is a risk factor for development 
of secondary malignancy in patients (pts) undergoing SCT for 
aplastic anemia. This risk is higher in FA pts because of their 
defective DNA repair mechanisms. In May 1999, we began a 
prospective study with low dose CY and ATG for conditioning 
FA pts without radiation and report here our results. Patients and 
Methods: From May 1999 through August 2002, 15 pts with FA 
underwent allogeneic SCT at KFSH&RC. Median age was 8.3 
years (range, 5.2-15 years). Diagnosis was confirmed by chromo- 
somal breakage studies with Mitomycin-c and Diepoxybutane 
(DEB). All pts had bone marrow examination before SCT and 
none had evidence of leukemia, myelodysplasia, or any clonal 
abnormalities. All pts had fewer than 12 blood product ransfu- 
sions in the year before BMT. Fourteen donors were HLA-iden- 
tical siblings, and one was an HLA identical father. All donors 
had negative chromosomal breakage studies. Harvested marrows 
were not manipulated, and the median CD 34 dose was 6.6 x 10 ° 
(range, 2.1-24 x 10 <' ) per kg of recipient body weight. The condi 
tioning was with CY 15 mg/kg/day i.v. for 4 days, and ATG 40 
lng/kg i.v. for 4 days. Graft vs. Host disease (GVItD) prophyla~s 
was with Cyclosporin and ATG (20 mg/kg for 6 doses post SCT). 
Donor engraftment was evaluated on day +28 by showing trilin- 
eage engraftment in the bone marrow and by VNTR analysis (for 
same sex SCT) or FISH (for opposite sex SCT) on peripheral 
lymphocytes. Results: All pts engrafted and are now alive and 
transfusion independent with a median follow up time of 15.5 
months (range, 1.2- 41.5 months). Median time to engraftment 
(ANC of > 0.SX10';/L) was 12 days (range, 9-28 days), median 
time to self sustaining platelet count of > 20X10VL was 30 days 
(range, i6-139 days). Three pts developed acute skin GVtID 
(grade 2) and one developed sldn and gut aGVHD(grade 2), all 
pts responded steroids. Thus far, no patients developed chronic 
GVHD. Mncositis grade > 2 developed in all pts. Four patients 
developed hemorrhagic cystitis. Conclusions: Use of radiation can 
be avoided in the conditioning of pts with FA undergoing Allo- 
geneic SCT. Low dose cyclophosphamide at 60 mg/kg with ATG 
can result in good engraftment with reas'onably tolerated to,city. 
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PROSPECTIVE MRD MONITORING BY RQ-PCR; CLINICAL FEASIBILITY 
IN EARLY DETECTION AND MANAGEMENT OF CML RELAPSE AFTER 
ALLOGENEIC SCT 
Kiln, D.; Kiln, Y.; Lee, S.; Kiln, t~; H~,a~g, .7.; Khan, C. Catholic 
He~atopoietic Ste~ Cell Trcm,s~h~tatio~z Ce*~ter, The Catholic UMver- 
sity of Korea, Sem,l, So~ttl, Korea. 
Background and Objectives. Immunotherapy at early phase 
relapse after stem cell transplantation (SCT) for chronic mye]ogc- 
nous leukemia (CML) induces ahigher ate of complete remission 
and lower side effects. Real-time quantitative RT-PCR (RQ- 
PCR) has been l~lown to be useful for early detection of CML 
recurrence. However, there has been no consensus about at which 
level RQ-PCR at early period after SCT immunotherapy should 
be given to prevent disease progression. Design and Methods. 
Using RQ-PCR, RT-PCR, and fluorescence in situ hybridization 
(FISH), we prospectively monitored minimal residual disease 
(MRD) in consecutive 45 patients who underwent SCT for CML. 
Patients with quantitative molecular elapse (QMR, rising BCR- 
ABL/ABL>0.01) were randomly assigned to either ,z0 therapy 
(group A) or i~ltTHzHlotherapy (group B) arm. Disease progression to 
molecular cytogenetic relapse (MCR, FISH>5.24%) was com- 
pared between two groups, hnnrunotherapy of immunosuppres- 
sants withdrawal, DLI (CD3+, 1.0 X 10e'/kg), and/or interferon 
was given to patients in group A when disease progressed to 
MCR, as it was given at he time of diagnosis to those in group B 
or initially relapsed MCR Results. 13 patients were diagnosed as 
QMR at a median of 3 months (2.8-6.3 months) post-HSCT. 
MCR occurred in all 6 in group A and 2 of 7 in group B following 
QMR, meanwhile 4 were diagnosed as initial MCR. The probabil- 
ity of MCR was significantly different between two groups (group 
A 100% vs group B 35.7%, P=0.002). Molecular emission (MR) 
was achieved in 11 (64.8%) of 17 patients at a median of 3.3 
months (i.2-11.4 months) after immunotherapy. The probability 
of disease free survival in 11 patients in MR was 87.5%; 10 of 11 
patients remain alive in MR more than 7.5 23.2 months. Acute 
and chronic GVHD developed in 29.4 % and 76.5%, respectively, 
and marrow suppression, on the contrary, did not develop. Treat- 
ment related to,cities developed in 2 patients (11.8%) Interpreta- 
tion and Conclusions. The fact that normalized BCR-ABL trau- 
script rising higher than 0.01 within 6 months after SCT heralded 
disease progression and substantial of the relapsed achieved 
molecular emission after early imlnunotherapy with reduced 
intensity revealed that RQ-PCR is a powerful tool in MRD moni- 
toring and managing CML relapse after SCT. 
46 
COMPARATIVE OUTCOME OF UNRELATED HEMATOPOIETIC STEM 
CELL TRANSPLANTATION (HSCT) WITH CORD BLOOD (CB) VS BONE 
MARROW (BM) IN PEDIATRIC RECIPIENTS 
Dr//e, j1;  D~wd, 3i.l; 3doghrabi, A.I; Roztsseau, p.2; ~'Vagller, E.l; 
f~tc'lao,~, M.1; Barrette, S. i, Ber'm'teiTz, M.1; Cha'mpa~lze, ,7.i David, 
M.1; De~;lers, ft. ;; ChaT;;pag;;e, AI.A. ; 1. Sai;;te av;;.rti;;e Hospital, ;!/Io;;- 
treal, QC, Ca~ada; 2. Notre Da'nm Hospital, MoTltreal, QC, Cmlada. 
From 06.1996 to 07.2002, 62 unrelated HSCT were undertaken 
in 57 children (36M/22F; median age 7.0 years.) at our institution. 
Stem cell source was CB in 33 and BM in 29. Forty-three patients 
had hematological 1-nalig~lancies and 14 inherited syndromes. HLA- 
A and -B typing was performed by serology for CB and molecularly 
for BM, whereas molecular typing' was used for HLA-DRbl for 
both. Donor-recipient HLA mismatches (MM) were only observed 
in CB-patients: 0 MM=I; 1MM =16; 2MM=16. Time from search 
initiation to HSCT was not differeut in the 2 cohorts, but time from 
decision to HSCT was 36 days shorter in CB recipients (p<0.0001). 
Conditioning regimens included cyclophosphamide with TBI or 
Busulfan _+ VP 16. ATG was administered for 57 transplants. GVt ID 
prophylaxis included cyclosporin + methotrexate for BM-patients, 
and cyclosporin +- steroids _+ methon'exate for CB-patients. Twenty 
CB patients received G-CSF. Supportive care guidelines were iden 
tical in the two groups. Primary graft failure occurred iu 6 CB and 3 
BM HSCT. Acute grade II to IV GVHI) occurred in 5 CB and 1 
BM recipients. Limited cGVHD occurred in 3 CB and 1 BM recipi- 
ents and no patients howed extensive cGVttD. Death occurred in 
12 CB-patients and 11BM patients (multiple organ failure=4 and 5, 
infection=4 and 1, relapse=t~ and 3, and other=l and ~,' respectively)., 
:l'hirty-four children are currently alive, 30 in CR, 3 in relapse and 1 
with autologous reconstitution (IIunter disease). Median time for 
engTaftement, Kaplan-Meicr TRM, OS and EFS are summarized in
table. We conclude that partially HLA-mismatched CB-HSCT is a 
suitable alternative to frilly HLA-lnatched BM-HSCT with no 
increased TRM and comparable outcomes. Consideration should be 
given for earlier selection of CB units for potential recipients. Table 
I summarizes the major clinical end-points: 
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